| Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls M Maruyama, H Shimada, T Suhara, H Shinotoh, B Ji, J Maeda, ... Neuron 79 (6), 1094-1108, 2013 | 827 | 2013 |
| 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer’s disease MT Fodero-Tavoletti, N Okamura, S Furumoto, RS Mulligan, AR Connor, ... Brain 134 (4), 1089-1100, 2011 | 399 | 2011 |
| 18F-THK5351: a novel PET radiotracer for imaging neurofibrillary pathology in Alzheimer disease R Harada, N Okamura, S Furumoto, K Furukawa, A Ishiki, N Tomita, ... Journal of Nuclear Medicine 57 (2), 208-214, 2016 | 356 | 2016 |
| Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease N Okamura, S Furumoto, R Harada, T Tago, T Yoshikawa, ... Journal of Nuclear Medicine 54 (8), 1420-1427, 2013 | 334 | 2013 |
| Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain KP Ng, TA Pascoal, S Mathotaarachchi, J Therriault, MS Kang, M Shin, ... Alzheimer's research & therapy 9, 1-9, 2017 | 330 | 2017 |
| 2-(2-[2-Dimethylaminothiazol-5-yl] ethenyl)-6-(2-[fluoro] ethoxy) benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients Y Kudo, N Okamura, S Furumoto, M Tashiro, K Furukawa, M Maruyama, ... Journal of Nuclear Medicine 48 (4), 553-561, 2007 | 305 | 2007 |
| Non-invasive assessment of Alzheimer’s disease neurofibrillary pathology using 18F-THK5105 PET N Okamura, S Furumoto, MT Fodero-Tavoletti, RS Mulligan, R Harada, ... Brain 137 (6), 1762-1771, 2014 | 304 | 2014 |
| Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer's disease N Okamura, T Suemoto, S Furumoto, M Suzuki, H Shimadzu, H Akatsu, ... Journal of Neuroscience 25 (47), 10857-10862, 2005 | 272 | 2005 |
| Glucose hypometabolism and neuropathological correlates in brains of dementia with Lewy bodies M Higuchi, M Tashiro, H Arai, N Okamura, S Hara, S Higuchi, M Itoh, ... Experimental neurology 162 (2), 247-256, 2000 | 254 | 2000 |
| In vivo evaluation of a novel tau imaging tracer for Alzheimer’s disease VL Villemagne, S Furumoto, MT Fodero-Tavoletti, RS Mulligan, J Hodges, ... European journal of nuclear medicine and molecular imaging 41, 816-826, 2014 | 209 | 2014 |
| Cerebrospinal fluid clearance in Alzheimer disease measured with dynamic PET MJ de Leon, Y Li, N Okamura, WH Tsui, LA Saint-Louis, L Glodzik, ... Journal of Nuclear Medicine 58 (9), 1471-1476, 2017 | 198 | 2017 |
| Tau PET imaging in Alzheimer’s disease N Okamura, R Harada, S Furumoto, H Arai, K Yanai, Y Kudo Current neurology and neuroscience reports 14, 1-7, 2014 | 193 | 2014 |
| The development and validation of tau PET tracers: current status and future directions N Okamura, R Harada, A Ishiki, A Kikuchi, T Nakamura, Y Kudo Clinical and translational imaging 6, 305-316, 2018 | 178 | 2018 |
| Histamine H1 receptors in patients with Alzheimer’s disease assessed by positron emission tomography M Higuchi, K Yanai, N Okamura, K Meguro, H Arai, M Itoh, R Iwata, T Ido, ... Neuroscience 99 (4), 721-729, 2000 | 170 | 2000 |
| Selective cognitive dysfunction in mice lacking histamine H1 and H2 receptors H Dai, K Kaneko, H Kato, S Fujii, Y Jing, A Xu, E Sakurai, M Kato, ... Neuroscience research 57 (2), 306-313, 2007 | 158 | 2007 |
| CSF phosphorylated tau protein and mild cognitive impairment: a prospective study H Arai, K Ishiguro, H Ohno, M Moriyama, N Itoh, N Okamura, T Matsui, ... Experimental neurology 166 (1), 201-203, 2000 | 156 | 2000 |
| Correlations of 18F-THK5351 PET with postmortem burden of tau and astrogliosis in Alzheimer disease R Harada, A Ishiki, H Kai, N Sato, K Furukawa, S Furumoto, T Tago, ... Journal of nuclear medicine 59 (4), 671-674, 2018 | 153 | 2018 |
| Functional neuroimaging of cognition impaired by a classical antihistamine, d-chlorpheniramine N Okamura, K Yanai, M Higuchi, J Sakai, R Iwata, T Ido, H Sasaki, ... British Journal of Pharmacology 129 (1), 115, 2000 | 153 | 2000 |
| In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with 18F-AV-133 N Okamura, VL Villemagne, J Drago, S Pejoska, RK Dhamija, ... Journal of Nuclear Medicine 51 (2), 223-228, 2010 | 151 | 2010 |
| Combined Analysis of CSF Tau Levels and [123I]Iodoamphetamine SPECT in Mild Cognitive Impairment: Implications for a Novel Predictor of Alzheimer’s Disease N Okamura, H Arai, M Maruyama, M Higuchi, T Matsui, H Tanji, T Seki, ... American Journal of Psychiatry 159 (3), 474-476, 2002 | 150 | 2002 |
